Skip to main content

Table 1 Clinical features of progressor and nonprogressor subgroup of EAA patients (according to data gained 12 months after diagnosis)

From: Bronchoalveolar lavage cell profiles and proteins concentrations can be used to phenotype extrinsic allergic alveolitis patients

 

Progressors

Nonprogressors

Number of cases

14

34

Clinical features

Age (years)

64.6 ± 10.5

60.3 ± 10.9

Gender (M/F)

8/6

25/9

Smoking status (N/ES)

4/10

11/33

FVC (% e.v.)

79.1 ± 21.6

76.7 ± 22.8

DLco (% e.v.)

50.2 ± 21.8

51.8 ± 7.0

BALF Lym (%)

15.6 ± 14.7

36.6 ± 27.6

Treatment

Systemic corticosteroids

8

9

Supportive care only

6

0

Avoidance of inhalation antigen only

0

25

  1. M Male, F female, N Nonsmoker, ES Ever smoked, FVC Forced vital capacity, DLco Diffusion capacity for carbon monoxide, e.v. expected value
  2. Definition of progression: significant decline of lung function (10% drop of FVC and/or 15% drop of DLco) or acute exacerbation or death in a 12-month period